MedPath

Metronidazole

Generic Name
Metronidazole
Brand Names
Flagyl, Flagystatin, Likmez, Metrocream, Metrogel, Metrolotion, Nidagel, Noritate, Nuvessa, Pylera, Rosadan, Vandazole
Drug Type
Small Molecule
Chemical Formula
C6H9N3O3
CAS Number
443-48-1
Unique Ingredient Identifier
140QMO216E
Background

Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.

Indication

Metronidazole is indicated for the treatment of confirmed trichomoniasis caused by Trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections. The above anaerobic infections may occur on the skin and skin structures, the abdomen, the heart, reproductive organs, central nervous system, and the respiratory system. Some may also be present in the bloodstream in cases of septicemia. Common infections treated by metronidazole are Bacteroides species infections, Clostridium infections, and Fusobacterium infections, as well as Peptococcus and Peptostreptococcus infections. Topical formulations of metronidazole are indicated for the treatment of inflammatory lesions of rosacea.

It is also used off-label in the treatment of Crohn's disease, as a prophylactic agent after surgery, and in the treatment of Helicobacter pylori infection. It has also been studied in the prevention of preterm births and to treat periodontal disease.

Associated Conditions
Abscess Brain, Abscess, Intra-Abdominal, Anaerobic Bacterial Infection, Bacterial Endocarditis, Bacterial Peritonitis, Bacterial Septicemia, Bacterial Vaginosis (BV), Balantidiasis, Bone and Joint Infections, Central Nervous System Bacterial Infections, Empyema, Endometritis, Endomyometritis, Facial Rosacea, Giardiasis, Gynecological Infection, Helicobacter Pylori Infection, Inflammatory Papule, Inflammatory pustules, Liver Abscess, Amebic, Lower respiratory tract infection bacterial, Lung Abscess, Meningitis, Mixed Vaginal Infections, Mixed Vaginal Infections caused by Trichomonas Vaginalis, candida albicans, Periodontitis, Pneumonia, Postoperative Infections, Pouchitis, Skin and skin structure infections, Tetanus, Trichomonas Vaginitis, Tubo-ovarian abscess, Vaginal Candidiasis, Vaginitis Trichomonal, Vulvovaginitis, Acute Intestinal amebiasis, Asymptomatic Trichomoniasis, Entamoeba histolytica, Hepatic abscess, Intra-abdominal bacterial infections, Post-surgical vaginal cuff infection, Refractory Sinusitis, Symptomatic Trichomoniasis

Evaluation of L-PRF as an Antibiotic Slow-release Biological Device in the Treatment of Moderate Periodontitis

Phase 2
Completed
Conditions
Periodontitis
Interventions
First Posted Date
2023-12-01
Last Posted Date
2023-12-01
Lead Sponsor
Yasmeen Khaled
Target Recruit Count
24
Registration Number
NCT06153706
Locations
🇪🇬

Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Vaginal LIve Biotherapeutic RANdomized Trial

Early Phase 1
Completed
Conditions
Bacterial Vaginosis
Interventions
First Posted Date
2023-11-18
Last Posted Date
2025-03-25
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
24
Registration Number
NCT06135974
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇿🇦

CAPRISA - Vulindlela, Msunduzi Municipality, KwaZulu Natal, South Africa

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

Phase 3
Recruiting
Conditions
Periodontal Diseases
Periodontitis
Periodontal Pocket
Interventions
First Posted Date
2023-11-14
Last Posted Date
2024-05-31
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
544
Registration Number
NCT06131021
Locations
🇺🇸

University of Alabame, Birmingham, Alabama, United States

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Phase 1
Recruiting
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
First Posted Date
2023-11-13
Last Posted Date
2025-04-24
Lead Sponsor
Institute of Cancer Research, United Kingdom
Target Recruit Count
39
Registration Number
NCT06126731
Locations
🇨🇭

Oncolgy Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

🇬🇧

The Royal Marsden NHS Foundation Trust, London Borough of Sutton, United Kingdom

Comparing the Efficacy of Metronidazole and Minocycline Gels for the Treatment of Diabetic Periodontitis Patients

Not Applicable
Completed
Conditions
Periodontitis
Diabetes Mellitus
Interventions
First Posted Date
2023-09-07
Last Posted Date
2023-09-07
Lead Sponsor
Riphah International University
Target Recruit Count
380
Registration Number
NCT06027151
Locations
🇵🇰

Islamic International Medical Collège, IIMC, Rawalpindi, Punjab, Pakistan

Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)

Phase 2
Not yet recruiting
Conditions
Appendicitis Perforated
Interventions
Drug: Piperacillin/tazobactam
Drug: Normal saline
First Posted Date
2023-07-13
Last Posted Date
2023-07-13
Lead Sponsor
McMaster Children's Hospital
Target Recruit Count
16
Registration Number
NCT05943223

Pharmacokinetics of Transdermal Metronidazole

Phase 4
Active, not recruiting
Conditions
Healthy
Interventions
Diagnostic Test: Transdermal water loss measurement
Diagnostic Test: Electrical Resistance
Diagnostic Test: Skin color measurement
Other: Micropatch application
First Posted Date
2023-07-03
Last Posted Date
2025-02-14
Lead Sponsor
University of Iowa
Target Recruit Count
24
Registration Number
NCT05929794
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

Not Applicable
Recruiting
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2023-07-03
Last Posted Date
2024-12-20
Lead Sponsor
Miguel O'Ryan Gallardo
Target Recruit Count
500
Registration Number
NCT05926804
Locations
🇨🇱

Universidad de Chile, Santiago, Chile

🇨🇱

Universidad de Aysén, Coyhaique, Chile

🇨🇱

Universidad de la Frontera, Temuco, Chile

Doxycycline for Helicobacter Pylori Rescue Treatment

Phase 4
Recruiting
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2023-05-25
Last Posted Date
2024-12-30
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
368
Registration Number
NCT05874570
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Rescue Therapy for Helicobacter Pylori Infection

First Posted Date
2023-05-25
Last Posted Date
2024-12-30
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
360
Registration Number
NCT05874544
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

🇨🇳

Shanghai Songjiang District Central Hospital, Shanghai, Shanghai, China

🇨🇳

The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath